NDA 019116 · Bausch
Locoid
Hydrocortisone Butyrate · Topical
Last checked: Nov 19, 2026Latest source record: Oct 30, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Feb 25, 1987
Approved uses
1
Original approval plus efficacy supplements
Registered trials
12
2 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 25, 1987 Original approval · Type 3 - New Dosage Form
1 products under this application
- LOCOID · HYDROCORTISONE BUTYRATE 0.1% · SOLUTION, TOPICAL · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydrocortisone Butyrate" as an intervention, any sponsor and status, largest first.
- Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic DermatitisPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00801957 · 260 participants · Start Mar 2003 · Primary completion Nov 2004
Drug: tacrolimus ointment 0.03%; hydrocortisone acetate ointment 1% and 3 more · For: Atopic Dermatitis
Sites: Kogarah, Australia; St Leonards, Australia; Benowa, Australia · 36 sites in all
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate ADPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT03539601 · 237 participants · Start Apr 27, 2018 · Primary completion Dec 11, 2020
Drug: Crisaborole ointment, 2%; Hydrocortisone butyrate cream, 0.1% and 2 more · For: Atopic Dermatitis
Sites: Bryant, Arkansas; Encinitas, California; Orange Park, Florida · 32 sites in all
- Clinical Evaluation of T.R.U.E. TEST® : Safety and EfficacyPivotal-lookingCompleted
AllerdermIndustry
NCT00640614 · 235 participants · Start Apr 2008 · Primary completion Aug 2009
Drug: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens · For: Contact Dermatitis
Sites: Little Rock, Arkansas; Shawnee Mission, Kansas; Louisville, Kentucky · 5 sites in all
- Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM)Pivotal-lookingStatus unknown
Peking Union Medical College HospitalAcademic, hospital or other
NCT03766997 · 100 participants (planned) · Start Feb 19, 2019 · Primary completion Jan 2021
Drug: Compound Betamethasone Injection; Hydrocortisone Butyrate 0.1% Cream · For: Granulomatous Mastitis
Sites: Beijing, China
- Medical and Surgical Treatment for Idiopathic Granulomatous MastitisPivotal-lookingStatus unknown
Peking Union Medical College HospitalAcademic, hospital or other
NCT02959580 · 100 participants (planned) · Start Jan 1, 2017 · Primary completion Sep 1, 2020
Drug: Hydrocortisone Butyrate · For: Granulomatous Mastitis
Sites: Beijing, China
MC2 TherapeuticsIndustry
NCT03758365 · 36 participants · Start Nov 5, 2018 · Primary completion Nov 23, 2018
Drug: MC2-01 Cream; Clobetasol Propionate 0.05% Lotion and 5 more · For: Vasoconstriction
Sites: Nice, France
LEO PharmaIndustry
NCT02973776 · 36 participants · Start Dec 2016 · Primary completion Feb 2017
Drug: LEO 90100 aerosol foam; Dermoval®/Dermovate® and 3 more · For: Psoriasis Vulgaris
Sites: Nice, France
Cairo UniversityAcademic, hospital or other
NCT03910088 · 30 participants · Start Apr 20, 2019 · Primary completion Jun 30, 2019
Drug: Pregabalin 100Mg Oral Cap; Hydrocortisone and 3 more · For: Post-Dural Puncture Headache
Sites: Cairo, Egypt
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Locoid trial.
Jackson N · Ir Med J 1975 · Clinical Trial, Controlled Clinical Trial
- The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis.
Caproni M, Torchia D, Antiga E, et al. · J Clin Immunol 2006 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis.
Veien NK, Hattel T, Justesen O, et al. · J Int Med Res 1984 · Clinical Trial, Comparative Study
- A clinical trial with hydrocortisone butyrate cream in psoriasis.
Polano MK, Suurmond D, von der Lely MA, et al. · Br J Dermatol 1970 · Clinical Trial, Comparative Study
- Anti-inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone.
Mose KF, Andersen F, Røpke MA, et al. · Br J Clin Pharmacol 2018 · Comparative Study, Randomized Controlled Trial
- Squamometry in seborrheic dermatitis.
Piérard-Franchimont C, Willemaers V, Fraiture AL, et al. · Int J Dermatol 1999 · Clinical Trial, Comparative Study
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.